News | Implantable Cardiac Monitor (ICM) | July 11, 2024

Amvia Sky Launched in Canada, the World’s First Pacemaker Approved for LBBAP

First implant of Amvia Sky in Canada performed at the Centre Hospitalier de l'Université de Montréal

First implant of Amvia Sky in Canada performed at the Centre Hospitalier de l'Université de Montréal

July 11, 2024 — Dr. Fadi Mansour performed the first Canadian implant of BIOTRONIK’s newest pacemaker and CRT-P generation earlier this year at the Centre Hospitalier de l'Université de Montréal. The patient received an Amvia Sky HF-T QP triple chamber pacemaker device. The first implant follows the full market release of BIOTRONIK’s newest family of pacemaker and CRT-P devices, featuring patient-centric technologies for better patient care and simplified workflows.

“The Amvia Sky HF-T QP offers a significant number of advanced features, making it the most complete CRT-P on the market including streamlined care pathways,” commented Dr. Mansour after the procedure.

The Amvia Sky system offers the following new features:

  • Industry-leading choice with 20 left ventricular (LV) pacing polarities, automatically tested in less than 2.5 minutes.
  • CRT AutoAdapt which automatically adjusts to changes in the patient’s condition for a more personalized response.
  • Enhanced Closed Loop Stimulation (CLS) rate adaptation technology.
  • Atrial arrhythmia management tools, including atrial antitachycardia pacing (ATP).
  • Streamlined Care Pathways.
  • Next-generation MRI access with MRI Guard 24/7.

“BIOTRONIK is dedicated to continually improving our technologies, and the Amvia Sky family is a great example of this commitment,” said Angela McGonigle, Country Director BIOTRONIK Canada. “Our latest family of pacemaker and CRT-P devices offers advanced features for optimized therapy and improved workflow simplification for Allied Health Professionals.”

For more information: www.biotronik.com


Related Content

News | Heart Failure

Oct. 22, 2025 – Ventric Health, a medtech innovator enabling early detection of heart failure (HF) in a primary care ...

Home October 28, 2025
Home
News | Heart Failure

Oct. 16, 2025 — Imbria Pharmaceuticals, has announced a partnership with the Hypertrophic Cardiomyopathy Association ...

Home October 16, 2025
Home
News | Heart Failure

Sept. 24, 2025 — The Family Heart Foundation, a leading research and advocacy organization, has announced the online ...

Home September 24, 2025
Home
News | Heart Failure

Sept. 22, 2025 — The latest findings on heart failure (HF) published by the Heart Failure Society of America (HFSA) ...

Home September 22, 2025
Home
News | Heart Failure

Sept. 11, 2025 — Newswise — A new Mayo Clinic study finds that many heart attacks in people under 65 — especially women ...

Home September 15, 2025
Home
News | Heart Failure

Aug. 14, 2025 — Analytics For Life, in collaboration with its U.S. commercial partner CorVista Health, announced they ...

Home August 15, 2025
Home
News | Heart Failure

Aug. 6, 2025 — Ventric Health, a medtech company enabling early detection of heart failure (HF) in a primary care ...

Home August 06, 2025
Home
News | Heart Failure

July 14, 2025 — Bayer has announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to ...

Home July 14, 2025
Home
News | Heart Failure

June 23, 2025 — iRhythm Technologies, Inc. announced the results from two large-scale real-world studies presented at ...

Home June 25, 2025
Home
News | Heart Failure

June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia (finerenone) clinical trial program ...

Home June 04, 2025
Home
Subscribe Now